in-vitro-diagnostics
(8)
The Million Tiny Doors Inside Axbio’s Machine
A physicist and a materials scientist put biology on a chip. Ten years later, Axbio is asking whether the economics of DNA reading can start to look like the economics of computing.
Virtue Diagnostics
Virtue Diagnostics is a platform-based in vitro diagnostics (IVD) company headquartered in Singapore, with manufacturing in Suzhou, China and clinical operations in Beijing. Founded in 2019, it develops affordable diagnostic instruments and reagents across chemiluminescence, clinical chemistry, hematology, clinical mass spectrometry, multiplex immunohistochemistry (mIHC) and molecular diagnostics, aiming to serve patients through every stage of disease - from early screening and diagnosis to treatment monitoring and minimal residual disease management. Its strategy centers on localized innovation and expansion in emerging markets including China, Singapore, Brazil, Indonesia and the Philippines. The company closed a US$100 million Series B round in January 2022 led by Sequoia China and Morningside Ventures.
Pearl Diagnostics, Inc.
Pearl Diagnostics is a Baltimore-based in vitro diagnostics company spun out of Johns Hopkins University that develops non-invasive urine tests to detect life-threatening lung infections. Its proprietary Smart Antibody technology identifies circulating microbial extracellular vesicles, and its lead product, the MycoMEIA Aspergillus Assay, became the first urine-based test to win FDA 510(k) clearance for aiding diagnosis of invasive aspergillosis. The company raised an $11.2M Series A in March 2026 to commercialize in the US and expand across Europe.
Calibra Scientific Inc.
Calibra Scientific Inc. (Hangzhou Calibra Diagnostics Co., Ltd., 凯莱谱) is a clinical mass spectrometry and multi-omics company that builds the full stack of precision diagnostics - instruments, reagent kits, reference materials and central-lab services. Founded in 2016 by Hua-fen Liu, a veteran of SCIEX, Roche and Pfizer, and backed as a DIAN Diagnostics company, Calibra has launched the NMPA-registered CalQuant-S mass spectrometry system, 10+ Class II reagent kits and 300+ clinical assays, serving more than 20,000 hospitals and research institutions across China.
RegDesk
RegDesk is an AI-powered regulatory information management platform for medical device, IVD, and pharma companies. It gives regulatory teams 24/7 access to up-to-date requirements across 120+ markets, automates submission-ready applications (GSPR checklists, Essential Principles, Declaration of Conformity), tracks changing regulations with daily alerts, and coordinates distributors - compressing submission work that once took three to six months into roughly a week.
Abhishek Ramkumar
Abhishek Ramkumar is the founder and CEO of Abram Scientific, a Menlo Park medtech company building CoagCare, a handheld point-of-care platform that reads the full blood-clotting story from a single drop in under ten minutes. A biomedical engineer with a PhD from Cornell and a B.Tech from IIT Bombay, he spent years at PARC and Blue Highway inventing diagnostic and surgical devices before turning a hard physics problem - measuring blood viscoelasticity and density in a vibration-proof wireless meter - into 17 granted patents and an $11.75M Series A led by Octapharma in 2026. His pitch is simple and life-or-death: get the right transfusion to the right patient at the right time, whether that patient is on an operating table or in a MEDEVAC helicopter.
Abram Scientific
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.
Inflammatix, Inc.
Inflammatix is a Sunnyvale, California molecular diagnostics company that reads the body's own immune response instead of hunting for the pathogen. Its FDA-cleared TriVerity test measures 29 host mRNAs from a blood sample and, using machine-learning algorithms, returns three scores in about 30 minutes: likelihood of bacterial infection, likelihood of viral infection, and overall illness severity. Run on the company's benchtop Myrna instrument, it is built for emergency and critical-care clinicians who need to decide fast whether a patient is heading toward sepsis. Spun out of Stanford in 2016, the company has raised more than $205M.